Make Plans to Attend our Annual Educational Meeting in Michigan near the Detroit Metro Airport
The Quinism Foundation is pleased to announce the date and location of our upcoming 2025 Annual Educational Meeting. This year’s meeting will be held at the Hilton Garden Inn, just minutes from the Detroit Metro Airport in Detroit, Michigan, on Monday, October 27th. Space is limited, so make your travel plans and register for the meeting today. Discounted registration of only $49 per person is available for a limited time.
For those traveling from out of town, we recommend arriving Sunday, October 26th and departing Tuesday, October 28th. Take advantage of a discounted block of rooms available at the meeting hotel, or consider booking directly at the Hilton Garden Inn or the neighboring pet-friendly Sheraton.
Free courtesy shuttles are available from the Detroit Metro Airport to each hotel, and a variety of meal options are available at each hotel and within walking distance of each. Unlike our previous meetings in Vermont, for those flying in, no rental car is needed!
This year’s meeting will feature a variety of educational sessions and open discussions, as well as complimentary coffee, light snacks, and other refreshments.
Questions? Please don’t hesitate to contact us for more information. We look forward to welcoming back prior attendees and welcoming new attendees to our new home in Michigan.
The Quinism Foundation Calls for Mefloquine Screening under the PACT Act
The Quinism Foundation is calling on the VA to screen recent veterans for a history of symptomatic exposure to mefloquine under the toxic exposure screening provisions of section 603 of the Promise to Address Comprehensive Toxics (PACT) Act.
As described in our recent press release, implementing screening for symptomatic exposure under Section 603 of the PACT Act can be as simple as the VA asking the veteran, “Did you take mefloquine,” and if so, “While you were taking the drug, did you experience one or more psychiatric symptoms, such as abnormal dreams or nightmares, insomnia, anxiety, depression, restlessness, or confusion?”
If the veteran reports symptomatic exposure, VA clinicians should retain an index of suspicion that any chronic neurologic or psychiatric symptoms, including those reported, could represent effects of mefloquine neurotoxicity.
